# A Rollover Study of NBM-BMX in Combination With Temozolomide in Patients With Newly Diagnosed Glioblastoma

> **NCT07569042** · PHASE1,PHASE2 · RECRUITING · sponsor: **Novelwise Pharmaceutical Corporation** · enrollment: 15 (estimated)

## Conditions studied

- Malignant Neoplasm of Brain

## Interventions

- **DRUG:** NBM-BMX Capsule
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT07569042
- **Lead sponsor:** Novelwise Pharmaceutical Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-20
- **Primary completion:** 2029-09-30
- **Final completion:** 2030-12-31
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07569042

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07569042, "A Rollover Study of NBM-BMX in Combination With Temozolomide in Patients With Newly Diagnosed Glioblastoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07569042. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*